Literature DB >> 3302713

Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity.

S B Soumerai, J Avorn, D Ross-Degnan, S Gortmaker.   

Abstract

In an attempt to contain costs, 27 Medicaid programs have implemented patient-level payment limits for medications, but the effects of these restrictions on quality of care, costs, and health status remain largely unknown. We measured the effect of one state's limit of three paid prescriptions per month and its replacement a year later by a $1 copayment. Using data on 48 months of claims in the study state (New Hampshire) and a comparison state (New Jersey), we employed time-series analysis to evaluate patient-level changes in the number of prescriptions filled for 16 drugs that varied in their clinical importance and cost. Among 10,734 continuously enrolled patients, the limit of three paid prescriptions per month caused a sudden, sustained drop of 30 percent in the number of prescriptions filled (from 1.10 to 0.77 prescriptions per patient per month); no change was observed in the comparison state. The 860 recipients of multiple drugs, who were predominantly female and elderly or disabled, were most severely affected; the number of prescriptions per month dropped from 5.2 to 2.8 (46 percent). The decrease was greatest for "ineffective drugs" (58 percent), but large drops were also observed for "essential" medications, such as insulin (28 percent), thiazides (28 percent), and furosemide (30 percent). Reductions in Medicaid prescriptions were minimally offset by increases in the size of the prescription or in out-of-pocket payments. When a $1 copayment replaced the three-prescription cap, prescriptions for most medications increased to just below precap levels. Medicaid's savings on drug costs resulting from both policies were comparable ($0.4 to $0.8 million annually), but the copayment policy had less effect on patients receiving multiple drugs. Because the clinical consequences of such policies cannot be assessed from prescription data alone, further study is needed to determine the effects of cost-containment strategies on health status and the use of other services among poor populations.

Entities:  

Mesh:

Year:  1987        PMID: 3302713     DOI: 10.1056/NEJM198708273170906

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  103 in total

1.  Changing doctor prescribing behaviour.

Authors:  P S Gill; M Mäkelä; K M Vermeulen; N Freemantle; G Ryan; C Bond; T Thorsen; F M Haaijer-Ruskamp
Journal:  Pharm World Sci       Date:  1999-08

2.  Medicare prescription coverage and congressional gridlock.

Authors:  S B Soumerai; A S Adams; D Ross-Degnan
Journal:  J Gen Intern Med       Date:  2001-12       Impact factor: 5.128

3.  Income-based drug benefit policy: impact on receipt of inhaled corticosteroid prescriptions by Manitoba children with asthma.

Authors:  A L Kozyrskyj; C A Mustard; M S Cheang; F E Simons
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

Review 4.  Pharmaceutical policies in Canada. Issues and challenges.

Authors:  D E Angus; H M Karpetz
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

5.  Pharmaceutical cost containment with reference-based pricing: time for refinements.

Authors:  Sebastian Schneeweiss; Malcolm Maclure; Colin Dormuth; Jerry Avorn
Journal:  CMAJ       Date:  2002-11-26       Impact factor: 8.262

Review 6.  Consumer-directed health care: will it improve health system performance?

Authors:  Karen Davis
Journal:  Health Serv Res       Date:  2004-08       Impact factor: 3.402

7.  Glycemic self-monitoring and insurance coverage.

Authors:  Michele Heisler
Journal:  CMAJ       Date:  2004-07-06       Impact factor: 8.262

8.  Impact of state laws that extend eligibility for parents' health insurance coverage to young adults.

Authors:  Alexander B Blum; Lawrence C Kleinman; Barbara Starfield; Joseph S Ross
Journal:  Pediatrics       Date:  2012-02-13       Impact factor: 7.124

Review 9.  Cost of pharmacological care of the elderly: implications for healthcare resources.

Authors:  Ciaran O'Neill; Carmel M Hughes; James Jamison; Anna Schweizer
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Risk factors in geriatric drug prescribing. A practical guide to avoiding problems.

Authors:  M H Beers; J G Ouslander
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.